What is the evidence‑based management plan for heart failure with reduced ejection fraction?

Evidence-Based Management of Heart Failure with Reduced Ejection Fraction

All patients with HFrEF (LVEF ≤40%) should receive simultaneous initiation of four foundational medication classes—ARNI (or ACE-I/ARB), beta-blocker, mineralocorticoid receptor antagonist, and SGLT2 inhibitor—at low doses within 2-4 weeks of diagnosis, with rapid uptitration every 1-2 weeks to target doses, which reduces 2-year mortality by approximately 73% compared to no treatment. 1, 2

Core Pharmacologic Therapy (Quadruple GDMT)

1. Renin-Angiotensin System Inhibition

Sacubitril/valsartan (ARNI) is strongly preferred over ACE inhibitors or ARBs, providing ≥20% mortality reduction versus the 5-16% reduction with ACE-I/ARB alone. 1, 2, 3

• Starting dose: Sacubitril/valsartan 49/51 mg twice daily 1
• Target dose: 97/103 mg twice daily 1, 2
• Critical safety requirement: 36-hour washout period when switching from ACE-I to avoid angioedema 2

If ARNI is not tolerated or available, use ACE inhibitors at evidence-based doses:

• Enalapril: start 2.5 mg twice daily, target 10-20 mg twice daily 1
• Lisinopril: start 2.5-5 mg daily, target 20-35 mg daily 1
• Ramipril: start 2.5 mg daily, target 10 mg daily 1

ARBs are reserved for ACE-I intolerant patients (typically due to cough):

• Candesartan: start 4-8 mg daily, target 32 mg daily 1
• Valsartan: start 40 mg twice daily, target 160 mg twice daily 1

2. Evidence-Based Beta-Blockers

Only three beta-blockers have proven mortality benefit (≥20% reduction) and should be used: 1, 2, 3

• Carvedilol: start 3.125 mg twice daily, target 25-50 mg twice daily 1, 2
• Metoprolol succinate (CR/XL): start 12.5-25 mg daily, target 200 mg daily 1, 2
• Bisoprolol: start 1.25 mg daily, target 10 mg daily 1, 2

Critical pitfall: Metoprolol tartrate (immediate-release) has never shown mortality benefit in HFrEF and should not be used. 3

3. Mineralocorticoid Receptor Antagonists (MRAs)

Spironolactone or eplerenone provide ≥20% mortality reduction and reduce sudden cardiac death. 1, 2, 3

• Spironolactone: start 12.5-25 mg daily, target 50 mg daily 1, 2
• Eplerenone: start 25 mg daily, target 50 mg daily 1
• Eplerenone advantage: No gynecomastia (10% incidence with spironolactone) 2

4. SGLT2 Inhibitors

Dapagliflozin or empagliflozin are the newest foundational therapy with significant mortality benefits, minimal blood pressure effects, and rapid onset (benefits within weeks). 1, 2, 3

• Dapagliflozin: 10 mg once daily (no titration required) 2
• Empagliflozin: 10 mg once daily (no titration required) 2
• Key advantage: Can be used with eGFR ≥20 mL/min/1.73 m² (dapagliflozin) or ≥30 mL/min/1.73 m² (empagliflozin) 2, 3

Diuretics for Volume Management

Loop diuretics are essential for congestion relief but do not reduce mortality. 1, 3

• Furosemide: start 20-40 mg once or twice daily, maximum 240 mg daily 1, 3
• Torsemide: start 5-10 mg daily, usual dose 10-20 mg daily 1
• Bumetanide: start 0.5-1.0 mg once or twice daily, maximum 5 mg daily 1

Titrate diuretics to achieve euvolemia (no edema, no orthopnea, no jugular venous distension), then use the lowest dose that maintains this state. 3

Rapid Initiation Strategy

Standard Blood Pressure (SBP >100 mmHg)

Step 1 (Day 0-7): Start SGLT2 inhibitor AND MRA simultaneously—these have minimal blood pressure effects. 2, 3, 4

Step 2 (Week 2): Add low-dose beta-blocker AND low-dose ARNI (or ACE-I if ARNI not available). 2, 5

Step 3 (Weeks 3-12): Uptitrate one drug at a time every 1-2 weeks using small increments until target or maximally tolerated dose achieved. 2, 4

Low Blood Pressure (SBP 80-100 mmHg with adequate perfusion)

Never withhold GDMT for asymptomatic hypotension when perfusion is adequate—patients can safely tolerate SBP 80-100 mmHg. 2, 3

Modified sequencing for low BP:

1. Start SGLT2 inhibitor and MRA first (minimal BP impact: SGLT2i lowers SBP by only 1.5 mmHg in patients with baseline SBP 95-110 mmHg) 2, 3
2. Add beta-blocker only if resting heart rate >60 bpm 2, 3
3. Add ARNI/ACE-I last, at very low doses 2, 3
4. Discontinue non-essential BP-lowering medications (alpha-blockers for BPH, unnecessary antihypertensives) 2, 3

Monitoring Requirements

After each dose increment, check at 1-2 weeks: 1, 2, 4

• Blood pressure and heart rate
• Serum creatinine and eGFR
• Serum potassium

Acceptable laboratory changes during uptitration:

• Creatinine increase up to 30% above baseline is acceptable and should not prompt discontinuation 2, 3
• Potassium <5.5 mEq/L is generally safe; use potassium binders (patiromer) rather than stopping MRA if hyperkalemia develops 3

Adjunctive Therapies for Specific Populations

Self-Identified Black Patients with NYHA Class III-IV

Add hydralazine/isosorbide dinitrate to quadruple therapy: 2, 3

• Hydralazine: start 25 mg three times daily, target 75 mg three times daily
• Isosorbide dinitrate: start 20 mg three times daily, target 40 mg three times daily

Persistent Symptoms Despite Optimal GDMT

Ivabradine may be added if: 1, 2, 3

• Sinus rhythm with resting heart rate ≥70 bpm
• NYHA class II-III symptoms
• Already on maximally tolerated beta-blocker
• Dosing: start 5 mg twice daily, target 7.5 mg twice daily 1

Critical caveat: Only 25% of ivabradine trial participants were on optimal beta-blocker doses—beta-blocker uptitration must precede ivabradine. 2

Device Therapy

Implantable Cardioverter-Defibrillator (ICD)

Indicated for primary prevention when: 3

• LVEF ≤35% despite ≥3 months of optimal medical therapy
• NYHA class II-III symptoms
• Expected survival >1 year with good functional status
• Ischemic cardiomyopathy or non-ischemic cardiomyopathy

Cardiac Resynchronization Therapy (CRT)

Class I indication (strongest recommendation): 1, 3

• LVEF ≤35%
• Sinus rhythm
• QRS duration ≥150 msec with left bundle branch block (LBBB) morphology
• NYHA class II-IV symptoms despite optimal medical therapy

Critical Pitfalls to Avoid

1. Delaying simultaneous initiation—less than 25% of eligible patients receive all four medications concurrently, and only 1% achieve target doses. 2, 3

2. Accepting suboptimal doses—target doses provide the greatest mortality benefit; clinical trials demonstrated benefits at target doses, not low doses. 2, 3

3. Stopping GDMT for asymptomatic hypotension—adverse events occur in 75-85% of HFrEF patients regardless of treatment, with no substantial difference between GDMT and placebo. 3

4. Using non-evidence-based beta-blockers—only carvedilol, metoprolol succinate, and bisoprolol reduce mortality; metoprolol tartrate, atenolol, and nebivolol do not. 2, 3

5. Combining ACE-I + ARB + MRA—this triple combination is contraindicated due to extreme hyperkalemia risk. 2, 3

6. Using diltiazem or verapamil—these non-dihydropyridine calcium channel blockers increase risk of worsening heart failure and are contraindicated in HFrEF. 3

7. Premature discontinuation for laboratory changes—modest creatinine elevation (up to 30%) and potassium <5.5 mEq/L are acceptable during uptitration. 2, 3

Expected Outcomes with Optimal Therapy

Combined quadruple therapy provides: 1, 2

• 73% reduction in 2-year mortality compared to no treatment
• 61% reduction in all-cause mortality (HR 0.39,95% CI 0.32-0.49)
• Approximately 6 additional life-years compared to traditional dual therapy
• 5.3 additional life-years compared to no disease-modifying therapy

Special Considerations

Hospitalized Patients

Continue GDMT except when hemodynamically unstable or contraindicated. 2, 4

In-hospital initiation substantially improves post-discharge medication use compared to deferring initiation to outpatient setting. 2

Initiate GDMT after ≥24 hours of stabilization with adequate organ perfusion. 2

Patients with Improved EF (HFmrEF, LVEF 41-49%)

Continue all HFrEF medications—discontinuation after EF improvement leads to clinical deterioration. 1, 2

SGLT2 inhibitors have Class 2a recommendation for HFmrEF based on EMPEROR-Preserved subgroup analysis. 1

Elderly Patients (≥75 years)

All four medication classes remain indicated, but require more frequent monitoring of blood pressure, renal function, and electrolytes during uptitration. 1, 2

Real-world data confirm benefit across all age groups, including patients ≥90 years. 6